Author(s):
Jyoti Devi, Shilpa, Sanjiv Duggal
Email(s):
somasharma378@gmail.com
DOI:
10.52711/0974-4150.2026.00067 
Address:
Jyoti Devi, Shilpa*, Sanjiv Duggal
Global College of Pharmacy, Kahnpur Khui, Anandpur Sahib, Punjab, 140117, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Mood disorders are a major global health burden contributing significantly to disability and are projected to become one of the leading causes of disease worldwide. They are characterized by persistent sadness, loss of interest, low self-esteem, neuro-vegetative changes suicidal thoughts and cognitive impairments such as negative bias and poor working memory. Clinically they mainly include major depressive disorder and bipolar disorder the latter marked by alternating mania or hypomania and depressive episodes. Current research suggests that mood disorders arise from complex multi-factorial mechanisms involving genetic, neurochemical, and environmental factors. Neuroimaging studies highlight dysfunction in brain regions such as the prefrontal cortex, amygdala, and hippocampus with reduced hippocampal volume and impaired neuroplasticity playing key roles in their patho-physiology. Among various pharmacological approaches, selective serotonin reuptake inhibitors are considered first-line therapeutic agents for the management of depressive and anxiety-related disorders. Current evidence also suggests that SSRIs may promote neuroplasticity and may influence structural brain changes, particularly in regions such as the hippocampus and prefrontal cortex. This review highlights the pharmacological mechanisms, clinical applications, therapeutic benefits and some marketed drug for SSRIs in the treatment of mood disorders. Overall, SSRIs remain a cornerstone in modern psychopharmacology for managing depressive and anxiety spectrum disorders.
Cite this article:
Jyoti Devi, Shilpa, Sanjiv Duggal. Selective Serotonin Reuptake Inhibitors for Treatment of Mood Disorders. Asian Journal of Research in Chemistry. 2026; 19(5):463-0. doi: 10.52711/0974-4150.2026.00067
Cite(Electronic):
Jyoti Devi, Shilpa, Sanjiv Duggal. Selective Serotonin Reuptake Inhibitors for Treatment of Mood Disorders. Asian Journal of Research in Chemistry. 2026; 19(5):463-0. doi: 10.52711/0974-4150.2026.00067 Available on: https://www.ajrconline.org/AbstractView.aspx?PID=2026-19-5-8
REFERENCES:
1. Murray CJ, Lopez AD. Evidence-based health policy--lessons from the Global Burden of Disease Study. Science. 1996 Nov 1; 274(5288): 740-3. doi: 10.1126/science.274.5288.740.
2. The Practice, of ECT. Recommendations for Treatment Training and Privileging. Convulse There 1990; 6(2): 85-120.DOI:10.1097/00124509-200203000-00015.
3. Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007 Sep; 10(9): 1110-5. doi: 10.1038/nn1969.
4. Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues ClinNeurosci. 2008; 10(4): 385-400. doi: 10.31887/DCNS.2008.10.4/gracagni.
5. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 Results. Seattle, United States: Institute for Health Metrics and Evaluation; 2021.doi:10.1016/SO120-6736(20)30925-9.
6. Marx W, Manger SH, Blencowe M, Murray G, Ho FY, Lawn S, Blumenthal JA, Schuch F, Stubbs B, Ruusunen A, Desyibelew HD, Dinan TG, Jacka F, Ravindran A, Berk M, O'Neil A. Clinical guidelines for the use of lifestyle-based mental health care in major depressive disorder: World Federation of Societies for Biological Psychiatry (WFSBP) and Australasian Society of Lifestyle Medicine (ASLM) taskforce. World J Biol Psychiatry. 2023; 24(5): 333-386.doi: 10.1080/15622975.2022.2112074.
7. Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. Lancet. 2003; 401(10371): 141-153. doi: 10.1016/S0140-6736(22)02080-3.
8. López-Muñoz F, Alamo C, Juckel G, Assion HJ. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. J Clin Psychopharmacol. 2007; 27(6): 555-9. doi:10.1097/jcp.0b013e3181bb617.
9. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. 2004;10(4): 239-48.doi:10.1097/00131746-200407000-00005.
10. Ban TA. In memory of three pioneers. Int J Neuropsychopharmacol. 2006; 9: 475–477. doi: 10.1017/S1461145706006870.
11. Barbui C, Guaiana G, Hotopf M. Amitriptyline for inpatients and SSRIs for outpatients with depression? Pharmacopsychiatry. 2004; 37: 93-97.doi: 10.1055/s-2004-818985.
12. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther. 2006; 110: 135370.doi: 10.1016/j.pharmthera.2005.11.006.
13. Wiles NJ, Fischer K, Cowen P, Nutt D, Peters TJ, Lewis G, White IR. Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram vs reboxetine): an example from the GENPOD trial. Psychol Med. 2014; 44: 2855–2866. Doi: 10.1017/S0033291714000221.
14. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA. 15 years of clinical experience with bupropion HCl: from bupropion-to-bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7: 106-113. Doi:10.4088/pcc. v07n0305.
15. Chakrabarti S. Bipolar disorder in the International Classification of Diseases-Eleventh version: A review of the changes, their basis, and usefulness. World J Psychiatry. 2022 Dec 19; 12(12): 1335-1355.doi: 10.5498/wjp. v12.i12.1335.
16. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011 Mar; 68(3): 241-51. Doi:10.1017/S00332917150004.
17. Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, Hopwood M, Lyndon B, Mulder R, Porter R, Singh AB, Murray G. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Bipolar Disorders. 2021; 55(1): 7-117. Doi:10.1177/0004867420979353.
18. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Chou JC, Keck PE, Rhodes LJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry. 2000; 57: 481–489. https://doi.org/10.1097/yic.0b013e3282fd827.
19. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: Results of the MAP study. Neuropsychobiology. 2000; 42 (Suppl. 1): 2–10. Doi:10.1159/000054844.
20. Faay MDM, Czobor P, Sommer IEC. Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis. Neuropsychopharmacology. 2018; 43(12): 2340-2349. Doi: 10.1038/s41386-018-0161-2.
21. El-Mallakh RS, Nuss S, Gao D, Gao Y, Ahmad SC, Schrodt C, Adler C. Asenapine in the Treatment of Bipolar Depression. Psychopharmacol Bull. 2020; 50(1): 8-18. doi: 10.64719/pb.4597.
22. Bowden CL.The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder. Neuropsychiatr. Dis. Treat. 2011; 7: 87–92. Doi:10.2147/NDT.S9932.
23. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience. 5(7): 553–64. doi:10.1038/nrn1430.
24. Kammerer M, Rassner MP, Freiman TM, Feuerstein TJ. Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes. Naunyn-Schmiedeberg's Archives of Pharmacology. 384(1): 47–57. doi:10.1007/s00210-011-0636-8.
25. Chengappa KN, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Levin H, Moffa N, Delaney J, Brar JS. Topiramate as add-on treatment for patients with bipolarmania. Bipolar Disord. 1999; 1: 42-53. doi:10.1034/j.1399-5618.1999.10111. x.
26. Hong JSW, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, Harrison PJ, Cipriani A. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Mol Psychiatry. 2022; 27(3): 1339-1349. doi: 10.1038/s41380-021-01386-6.
27. Freeman HL. Historical and nosological aspects of dysthymia. Acta Psychiatr Scand Suppl. 1994; 383: 7-11. doi: 10.1111/j.1600-0447. 1994.tb05877. x.
28. Perugi G, Hantouche E, Vannucchi G, Pinto O. Cyclothymia reloaded: A reappraisal of the most misconceived affective disorder. J Affect Disord. 20151; 183: 119-33. doi: 10.1016/j.jad.2015.05.004.
29. Preskorn SH, Ross R, Stanga CY. Selective Serotonin Reuptake Inhibitors Antidepressants: Past, Present and Future. Berlin. Springer. pp. 241–262.ISBN 978-3-540-43054-4.Doi:10.1007/978-3-642-18500-7-9.
30. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023; 28(8): 3243-3256. doi: 10.1038/s41380-022-01661-0.
31. Lancet T. 50 years of SSRIs: weighing benefits and harms. The Lancet. 405(10490): 1641.doi:10.1016/S0140-6736(25)00981-X
32. Bertrand PP, Bertrand RL. Serotonin release and uptake in the gastrointestinal tract. Autonomic Neuroscience. 2010(16); 153(1,2): 4757.doi: 10.1016/j.autneu.2009.08.002.
33. Lepist EI, Ray AS. Beyond drug–drug interactions. Effects of transporter inhibition on endobiotics, nutrients and toxins. Expert Opinion on Drug MetabolismToxicology. 2017; 13(10) 1087. doi:10.1080/17425255.2017.1372425.
34. Shadfar S, Kim YG, Katila N, Neupane S, Ojha U, Bhurtel S, Srivastav S, Jeong GS, Park PH, Hong JT, Choi DY. Neuroprotective effects of antidepressants via upregulation of neurotrophic factors in the MPTP model of Parkinson’s disease. Molecular Neurobiology. 55(1): 554-556. doi:10.1007/s12035-016-0342-0.
35. David DJ, Gourion D. Antidépresseurs et tolérance :déterminants et prise en charge des principaux effets indésirables Antidepressant and tolerance: Determinants and management of major side effects. Encephale. 2016; 42(6): 553-561. French. doi: 10.1016/j.encep.2016.05.006.
36. Marken PA, Munro JS. Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features. Prim Care Companion J Clin Psychiatry. 2000; 2(6): 205-210. doi: 10.4088/pcc. v02n0602.
37. Sánchez C, Bøgesó KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology. 2004; 174: 163–176. Doi: 10.1007/s00213-004-1865-z.
38. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J. Clin. Psychiatry. 2009; 70: 1688–1697. Doi: 10.4088/JCP.08r04856blu.
39. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst. Rev. 2010; 4: CD006117. Doi: 10.1002/14651858.CD006117.
40. Claassen V, Davies JE, Hertting G, Placheta P. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol. 1977; 60(4): 505–516. Doi: 10.1111/j.1476-5381.1977.tb07528. X.